The telemedicine service Doctor on Demand is doubling down on its enterprise partnership business, and is taking a new $50 million injection of venture capital funding to do it.
The company is getting some traction with self-insured enterprises, who are offering the Doctor on Demand service to their employees as an add-on to their health insurance benefits.
Doctor on Demand will use the new investment money to market the existing service and to “build onto the enterprise sales team,” said cofounder and CEO Adam Jackson. “It’s a ‘just add water’ growth round,” he said.
Aerie Pharmaceuticals took a big step back earlier this year when its glaucoma drug came up short in the first of a few Phase 3 trials. But the Bedminster, NJ-based company still has a shot to bounce back, and got some needed news from the FDA that could help.
Ulcers aren’t caused by stress, but by a bacteria called Helicobacter pylori (H. pylori) – and Israeli biotech firm RedHill Biopharma on Monday announced that the latest study of its RHB-105 treatment showed that it was some 20 percent more effective in killing H. pylori than current treatment methods.
Israeli biotech firm RedHill Biopharma announced Monday that the latest study of its anti-ulcer treatment showed it to be some 20 percent more effective than current methods
As a result, RedHill’s stock soared more than 40% on the Tel Aviv Stock Exchange Monday, and was up a similar amount in pre-market trading on the NASDAQ, where it is dual-listed.
Korea’s Ministry of Health and Welfare unveiled a policy vision for the healthcare industry, which outlines the basic plan for each health sub-sector.
Presented during the ‘2015 Bio & Medical Korea’ held at the COEX Convention Center in Seoul last month, the ‘Healthcare Industry Promotion Plan’ is expected to boost Korea’s competitiveness in the healthcare industry.
A new study has revealed that tests for kidney function can be equally effective at indicating a patient's risk of heart disease as blood pressure or cholesterol tests. EurActiv France reports.
A new technology that re-creates important characteristics of structures in the lung could eventually be a safer alternative to certain types of respiratory and cardiac machines used to treat people whose lungs have failed due to disease or injury.
t’s no secret that there’s a huge need for more effective antibiotics. The number of bacteria evolving and evading current treatments continues to grow, and government agencies are trying to lend a helping hand. Spero Therapeutics has taken notice, and that’s why it’s thinking more broadly these days about the company it aims to become.
Cambridge, MA-based Spero today is announcing a $30 million Series A round from a group of new investors—Lundbeckfond Ventures (an evergreen fund and subsidiary of the Lundbeck Foundation), Merck Research Ventures, and The Kraft Group—and existing backers Atlas Venture, SR One (the VC arm of GlaxoSmithKline), and Partners Innovation Fund.
Bwom es un proyecto dedicado a empoderar a las mujeres a través de la toma de control de su salud pélvica. Está fundado, liderado y financiado exclusivamente por mujeres y ofrece planes fisioterapéuticos personalizados para el mantenimiento y la mejora de la salud de la zona pélvica a través de una atractiva app.
For the third year in a row, a life sciences startup took home the top prize at the Wisconsin Governor’s Business Plan Contest.
On Wednesday, Madison-based BluDiagnostics was named the competition’s overall winner and top life sciences company, beating 12 other finalists. All 13 teams presented Tuesday at the Wisconsin Entrepreneurs’ Conference held at Madison’s Alliant Energy Center, an annual two-day business conference hosted by the Wisconsin Technology Council.
Alors que les traitements actuels contre l'hypertension requièrent une prise de médicaments quotidienne - faute de quoi le patient s'expose à des risques de crise cardiaque ou d'AVC -, un vaccin développé par une équipe de chercheurs de l'université d'Osaka pourrait alléger considérablement les contraintes du traitement en ne requérant qu'une ou deux injections annuelles.
